Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44237   clinical trials with a EudraCT protocol, of which   7338   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-003947-27
    Sponsor's Protocol Code Number:TAK-981-1002
    National Competent Authority:Poland - Office for Medicinal Products
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2021-05-24
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedPoland - Office for Medicinal Products
    A.2EudraCT number2020-003947-27
    A.3Full title of the trial
    An Open Label, Dose-Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Pharmacokinetics of TAK-981 in Adult Patients With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Phase 1/2 Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Pharmacokinetics of TAK-981 in Adult Patients With Solid Tumors or Hematologic Malignancies
    A.4.1Sponsor's protocol code numberTAK-981-1002
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorTakeda Development Center Americas, Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportTakeda Development Center Americas, Inc. (TDC Americas)
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationTakeda Pharmaceuticals International, Co
    B.5.2Functional name of contact pointStudy Registration Center
    B.5.3 Address:
    B.5.3.1Street Address40 Landsowne Street
    B.5.3.2Town/ cityCambridge, MA
    B.5.3.3Post code02139
    B.5.3.4CountryUnited States
    B.5.4Telephone number+1 866 835 2233
    B.5.6E-mailGlobalOncologyMedInfo@takeda.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameTAK-981
    D.3.2Product code TAK-981
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 1858276-04-6
    D.3.9.2Current sponsor codeTAK-981
    D.3.9.4EV Substance CodeSUB218403
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
    E.1.1.1Medical condition in easily understood language
    Solid Tumors or Hematologic Malignancies
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 27.1
    E.1.2Level LLT
    E.1.2Classification code 10066481
    E.1.2Term Hematological malignancy
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Phase 1:To determine the safety and tolerability of TAK-981 as a single agent in patients with advanced or metastatic solid tumors and lymphomas. To establish the RP2D of TAK-981.
    Phase 2:To evaluate preliminary efficacy of TAK-981 in patients with select solid tumors or relapsed/refractory CD20+ NHL indications
    E.2.2Secondary objectives of the trial
    Phase 1:To assess the preliminary antitumor activity of TAK-981. To assess target engagement of TAK-981 (SUMO-TAK-981 adduct formation) and SUMOylation pathway inhibition in skin and peripheral blood cells. To characterize the PK profile of TAK-981.
    Phase 2:To evaluate the efficacy of TAK-981 in select solid tumor and CD20+ NHL indications as measured by overall response rate (ORR), time to response (TTR),DOR, duration of the response (DOR), disease control rate (DCR), time to progression (TTP), and progression-free survival (PFS). To evaluate overall survival (OS). To evaluate the safety and tolerability of TAK-981.To collect plasma concentration-time data for TAK-981.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Adult male or female patients ≥18 years old.
    2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
    3. Patient population for Phase 1 dose escalation:
    a. Have a histologically or cytologically confirmed advanced or metastatic solid tumors who have no standard therapeutic option with a proven clinical benefit, are intolerant, or have refused them.
    b. Have a relapsed/refractory lymphoma not amenable to therapies with proven clinical benefit or who are intolerant or who refuse them. Patients with low-grade lymphomas such as FL, small lymphocytic lymphoma, lymphoplasmacytoid lymphoma, and marginal zone lymphomas may not need to exhaust all available therapy. These patients can be enrolled after failure of at least 2 prior systemic therapies, provided that there is not an immediate need for cytoreduction. In these cases, patients who need immediate therapy for tumor bulk are not eligible for this trial.
    4. Patient population for Phase 2 dose expansion cohorts:
    Have a histologically or cytologically documented, advanced (metastatic and/or unresectable) cancer as listed below, which is incurable and for which prior standard first-line treatment has failed:
    a.Nonsquamous NSCLC that has progressed to 1 prior systemic immune checkpoint inhibitor (CPI)/anti-PD-(1/L1)-containing therapy and no more than 2 lines of therapy. Patients must have not shown evidence of tumor progression during the first 5 months of treatment with first-line CPI/anti-PD-(1/L1)-containing therapy (cohort A).
    b. CPI-naïve cervical cancer (squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix) patients who have received no more than 1 prior systemic line of therapy for recurrent or Stage IVB cervical cancer (cohort B).
    c. CPI-naïve MSS-CRC patients who have progressed on no more than 3 chemotherapy regimens (cohort C).
    d. Relapsed/refractory DLBCL progressed or relapsed after a prior CAR T-cell therapy that has received approval by a health authority for the treatment of DLBCL (Cohort D).
    e. Relapsed/refractory DLBCL that has progressed or relapsed after at least 2 but no more than 3 prior lines of systemic therapy and has not received prior cellular therapy. At least one prior line of therapy must have included a CD20-targeted therapy (cohort E).
    f. Relapsed/refractory FL that has progressed or relapsed after at least 2 but no more than 3 prior lines of systemic therapy. At least one prior line of therapy must have included a CD20-targeted therapy (cohort F).
    5. In Phase 2 only, have at least 1 radiologically measurable lesion based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) for patients with solid tumors or Lugano criteria for lymphoma. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
    6. In Phase 2 stage 1, willing to consent to mandatory pretreatment and on-treatment tumor biopsy.
    7. Is willing to provide archival tumor tissue sample, if available.
    8. Adequate bone marrow reserve and renal and hepatic function based on the following laboratory parameters:
    a. Absolute neutrophil count (ANC) ≥1.0 × 109/L, hemoglobin ≥85 g/L (red blood cell transfusion allowed ≥14 days before assessment), and platelet count ≥75.0 × 109/L(platelet count ≥50.0 × 109/L is allowed for patients with lymphoma if it is clearly due to marrow involvement with no evidence of myelodysplastic syndrome or hypoplastic bone marrow, if found).
    b. Total bilirubin ≤1.5 times the institutional upper limit of normal (ULN); or total bilirubin <3.0 times the ULN with direct bilirubin within normal range in patients with well documented Gilbert’s syndrome.
    c. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤3.0 times the ULN (<5 times the ULN if liver enzyme elevations are due to liver metastases).
    d. Estimated creatinine clearance using the Cockcroft-Gault formula ≥45 mL/min.
    9. Recovered to Grade 1 or baseline or established as sequelae from all toxic effects of previous therapy (except alopecia, neuropathy, or autoimmune endocrinopathies with stable endocrine replacement therapy, or bone marrow parameters [any of Grade 1/2 permitted if directly related to bone marrow involvement]).
    10. Consented to undergo serial skin punch biopsies .
    11. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.
    12. Suitable venous access for safe drug administration and the study-required PK and pharmacodynamic sampling.
    13. Women of childbearing potential participating in this study should avoid becoming pregnant
    See 14. Male patients contraception more details set out in protocol
    E.4Principal exclusion criteria
    1. Phase 1 dose escalation and Phase 2 cancer treatment expansion cohorts:
    a. Have received treatment with systemic anticancer treatments or investigational products within 14 days before the first dose of study drug or 5 half-lives, whichever is shorter.
    b. Have received extended field radiotherapy ≤4 weeks before the start of treatment (≤2 weeks for limited field radiation for palliation) and have not recovered to Grade 1 or baseline from related side effects of such therapy (except for alopecia).
    2. Have a history of uncontrolled brain metastasis. Patients with brain metastases are allowed if they are previously treated with surgery, whole-brain radiation, or stereotactic radiosurgery and the patients are receiving a corticosteroid dose ≤10 mg/day of prednisone equivalent at the time of receiving the first dose of TAK-981. For asymptomatic patients, screening brain imaging is not required.
    3. Patient is receiving any live vaccine (eg, varicella, pneumococcus) within 4 weeks of initiation of study treatment.
    4. History of any of the following ≤6 months before first dose: congestive heart failure New York Heart Association Grade III or IV, unstable angina, myocardial infarction, unstable symptomatic ischemic heart disease, severe noncompensated hypertension despite appropriate medical therapy, ongoing symptomatic cardiac arrhythmias of >Grade 2, pulmonary embolism, or symptomatic cerebrovascular events, or any other serious cardiac condition (eg, pericardial effusion or restrictive cardiomyopathy). Chronic atrial fibrillation on stable anticoagulant therapy is allowed.
    5. Baseline prolongation of the QT interval with Fridericia correction method (QTcF) (eg, repeated demonstration of QTcF interval >480 ms, history of congenital long QT syndrome, or torsades de pointes).
    6. Psychiatric illness/social circumstances that would limit compliance with study requirements and substantially increase the risk of AEs or has compromised ability to provide written informed consent.
    7. Admission or evidence of illicit drug use, drug abuse, or alcohol abuse.
    8. History of autoimmune disease requiring systemic immunosuppressive therapy with daily doses of prednisone >10 mg/day or equivalent doses, or any other form of immunosuppressive therapy. Hormone therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered an excluded form of systemic treatment of an autoimmune disease
    9. History of immune-related AEs related to treatment with immune checkpoint inhibitors that required treatment discontinuation.
    10. History of noninfectious pneumonitis that required steroids or a history of interstitial lung disease.
    11. Has evidence of active, noninfectious pneumonitis.
    12. Have a significant active infection.
    13. Known history of human immunodeficiency virus infection or any other relevant congenital or acquired immunodeficiency.
    14. Known hepatitis B virus (HBV) surface antigen seropositive or detectable hepatitis C infection viral load.
    15. Receiving or requiring the continued use of medications that are known to be strong or moderate inhibitors and inducers of CYP3A4/5 or are strong P-gp inhibitors at screening. To participate in this study, such patients should discontinue use of such agents for at least 2 weeks (1 week for CUP3A4/5 and P-gp inhibitors) or 5 times the half-life
    (whichever is shorter) before receiving a dose of TAK-981.
    16. Patient requires the use of drugs known to prolong QTc interval (during Phase 1 only) (Appendix H).
    17. History of allogeneic tissue or solid organ transplant.
    18. Second malignancy within the previous 3 years, except treated basal cell or localized squamous skin carcinomas, localized prostate cancer, cervical carcinoma in situ, resected colorectal adenomatous polyps, breast cancer in situ, or other malignancy for which the patient is not on active anticancer therapy.
    19. Female patients who are lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 before first dose of study drug.
    E.5 End points
    E.5.1Primary end point(s)
    Phase 1:
    Frequency, severity, and duration of TEAEs and laboratory abnormalities for all dose groups according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0 except CRS, which will be graded according to American Society for Transplantation and Cellular Therapy (ASTCT) Consensus Grading for CRS.
    DLTs within the first 21 days of treatment in Cycle 1.
    Phase 2:
    ORR (complete response [CR] + partial response [PR]) as defined by the investigator according to RECIST v1.1 criteria for solid tumors or Lugano classification for lymphomas.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Phase 1 and 2
    E.5.2Secondary end point(s)
    PK parameters after the first dose of TAK-981 on C1D1 and C1D8 (data permitting):
    – Maximum observed plasma concentration (Cmax).
    – Time of first occurrence of maximum observed plasma concentration (tmax).
    – Area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUClast).
    – Area under the plasma concentration-time curve from time 0 to infinity (AUC∞).
    – Terminal disposition phase half-life (t1/2z).
    – Total clearance (CL) after IV administration.
    – Vss.
    Phase 1:
    ORR, DCR, DOR, TTP, and PFS as assessed by the investigator according to RECIST v1.1 criteria for solid tumors or Lugano classification for lymphomas.
    TAK-981-SUMO adduct formation and SUMO pathway inhibition in skin/blood.
    Phase 2:
    Frequency, severity, and duration of TEAEs and laboratory abnormalities for all dose groups according to the NCI CTCAE version 5.0; except CRS which will be graded according to ASTCT Consensus Grading for CRS.
    DCR, DOR, TTR, TTP and PFS, and OS as assessed by the investigator according to RECIST v1.1 criteria for solid tumors or Lugano classification for lymphomas and OS.
    E.5.2.1Timepoint(s) of evaluation of this end point
    After the first dose of TAK-981, phase 1 and 2
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans Yes
    E.7.1.2Bioequivalence study No
    E.7.1.3Other Yes
    E.7.1.3.1Other trial type description
    Phase 1 occurs only in USA
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Ph1: cohort-based dose escalation with an adaptive design. Phase 2: 6 treatment cohorts of patients
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    Phase 1 (dose escalation), Phase 2 is a cancer treatment dose expansion with 6 treatment arms
    E.8.2.4Number of treatment arms in the trial7
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned9
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA42
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Ukraine
    China
    United Kingdom
    United States
    Belgium
    Poland
    Romania
    Spain
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The primary analyses for the primary endpoint will be conducted after all patients enrolled in the study have had the opportunity to complete 9 cycles of treatment with TAK-981. The final data cutoff for the clinical study report will be conducted after all patients have been discontinued from
    treatment or transferred to a long-term safety study, a single-patient investigational new drug application, or a similar program.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months8
    E.8.9.1In the Member State concerned days3
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months5
    E.8.9.2In all countries concerned by the trial days12
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 75
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 57
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state40
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 62
    F.4.2.2In the whole clinical trial 132
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Participants may continue to receive TAK-981 in an extension phase of this study or will be given the opportunity to enroll in a separate open-label rollover study or have the possibility of using an individual patient investigational new drug to continue receiving TAK-981. Additionally, these patients should have no alternative therapeutic option, and would be harmed without continued access.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-07-04
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-05-20
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2023-12-14
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA